BURLINGTON, Mass., Feb. 21 /PRNewswire-FirstCall/--
Palomar Medical Technologies Inc (Nasdaq: PMTI) today announced that a new
hand piece, the LUX G, used to treat vascular lesions with the Palomar
EsteLux(TM) light-based system will be shown for the first time at the
upcoming American Academy of Dermatology (AAD) meeting. The Company will be
presenting the LUX G along with its other latest products at the upcoming
American Academy of Dermatology's 60th Annual Meeting, in New Orleans, LA,
from February 23-26, 2002, and will be available to give investor
demonstrations and discuss its full line of products at booth #1915.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO )
The LUX G green light hand piece greatly expands the EsteLux's treatment
capabilities. The Palomar EsteLux light-based system can now be used for
removing hair and vascular and pigmented lesions. With an output spectrum
within the green wavelengths of light, the new LUX G is targeted at both
oxyhemoglobin and deoxyhemoglobin in the blood. The green light wavelength
spectrum is also highly absorbed by melanin, the pigment responsible for
tanning and for producing brown spots on the skin. The treatment of vascular
lesions (broken capillaries and rosecea) and the removal of pigmented lesions
(age-spots, sun damage, etc) has been successfully accomplished in the past
using a variety of green light lasers. Now, with the addition of the LUX G
hand piece to the EsteLux, both applications can be accomplished rapidly and
comfortably.
David Vasily, M.D., Medical Director of Aesthetica Cosmetic and Laser
Center in Bethlehem, PA, commented "The EsteLux has shown itself to be a fast
and effective treatment for hair and actinic bronzing including solar
lentigines, better known as age-spots or sunspots, and other sun related
dyschromia. Now with the addition of the new green light hand piece, it is
even easier to treat photo-damaged and pigmentation on the skin. Also, the
vascular component, comprised of small to medium sized broken blood vessels,
typically associated with sun-damaged skin can be effectively treated. It is
obvious to see that immediately following the treatment that the vessels are
gone. The pigmented area on the skin darkens slightly following the treatment
and over the course of the next week peel away revealing a healthy rejuvenated
epidermis. This creates the opportunity to treat both pigmented and vascular
components of sun damaged skin simultaneously and minimizes any downtime to
the patient."
About Palomar Medical Technologies Inc: Palomar is the leading researcher
and developer of laser/light based systems for hair removal and other cosmetic
treatments and is the first company to obtain clearance from the FDA for
"permanent hair reduction." Palomar systems have been installed in practices
worldwide, and hundreds of thousands of treatments have been performed. New
and exciting indications are being tested to further advance the hair removal
market and other cosmetic applications including fat reduction, acne treatment
and skin rejuvenation.
To get more information regarding Palomar and its products, please visit
Palomar's web site at http://www.palmed.com. Also, to continue to receive the most
up-to-date information and latest news on Palomar as it happens, sign up to
receive automatic e-mail alerts by going to the e-mail alerts page in the
Investor Relations' section of the web site.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products, the results of litigation,
potential infringement of third-party intellectual property rights, and/or
other factors, which are detailed from time to time in the company's SEC
reports, including the report on Form 10-K for the year ended December 31,
2000 and the Company's quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The company undertakes no obligation to release
publicly the result of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Contact:
Paul S. Weiner,
Treasurer
781-993-2411 or ir@palmed.com
SOURCE Palomar Medical Technologies Inc
 back to top
Related links:
http://www.palmed.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/107555.html
CONTACT:
Paul S. Weiner, Treasurer of Palomar Medical
Technologies Inc, +1-781-993-2411, ir@palmed.com
|
